Literature DB >> 3578430

Positive groin lymph nodes in superficial squamous cell vulvar cancer. A Gynecologic Oncology Group Study.

A Sedlis, H Homesley, B N Bundy, R Marshall, E Yordan, N Hacker, J H Lee, C Whitney.   

Abstract

The term microinvasive carcinoma is inappropriate when applied to all vulvar cancers less than or equal to 5 mm thick because approximately 50% of vulvar carcinomas are no thicker than 5 mm and 20% of those superficial tumors metastasize to the lymph nodes. The significant predictors of groin node metastases in patients with superficial vulvar cancer are tumor thickness, histologic grade (proportion of undifferentiated tumor pattern), capillary-like space involvement with the tumor, clitoral or perineal location, and clinically suspicious nodes, according to the linear logistic model analysis of clinicopathologic data in 272 women. No lymph node metastases occurred in approximately one fourth of patients with a combination of low-risk factors: no clinically suspicious nodes, negative capillary-like space, and nonmidline vulvar cancers that were either grade 1 and 1 to 5 mm thick or grade 2 and 1 to 2 mm thick. In contrast, all 10 patients with clinically suspicious nodes and grade 4 tumors had positive groin nodes. The risk of lymph node metastases is best determined by simultaneous evaluation of all risk factors rather than a single factor such as tumor thickness.

Entities:  

Mesh:

Year:  1987        PMID: 3578430     DOI: 10.1016/0002-9378(87)90132-3

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  7 in total

Review 1.  Primary groin irradiation versus primary groin surgery for early vulvar cancer.

Authors:  Jacobus van der Velden; Guus Fons; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2011-05-11

2.  Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study.

Authors:  Charles F Levenback; Shamshad Ali; Robert L Coleman; Michael A Gold; Jeffrey M Fowler; Patricia L Judson; Maria C Bell; Koen De Geest; Nick M Spirtos; Ronald K Potkul; Mario M Leitao; Jamie N Bakkum-Gamez; Emma C Rossi; Samuel S Lentz; James J Burke; Linda Van Le; Cornelia L Trimble
Journal:  J Clin Oncol       Date:  2012-07-02       Impact factor: 44.544

3.  A clinical and pathological overview of vulvar condyloma acuminatum, intraepithelial neoplasia, and squamous cell carcinoma.

Authors:  Boris Léonard; Frederic Kridelka; Katty Delbecque; Frederic Goffin; Stéphanie Demoulin; Jean Doyen; Philippe Delvenne
Journal:  Biomed Res Int       Date:  2014-02-25       Impact factor: 3.411

Review 4.  The giant steps in surgical downsizing toward a personalized treatment of vulvar cancer.

Authors:  Andrea Giannini; Ottavia D'Oria; Benito Chiofalo; Valentina Bruno; Ermelinda Baiocco; Emanuela Mancini; Rosanna Mancari; Cristina Vincenzoni; Giuseppe Cutillo; Enrico Vizza
Journal:  J Obstet Gynaecol Res       Date:  2021-12-28       Impact factor: 1.697

Review 5.  Lymphatic mapping and sentinel node biopsy in gynecological cancers: a critical review of the literature.

Authors:  Ali Ayhan; Husnu Celik; Polat Dursun
Journal:  World J Surg Oncol       Date:  2008-05-20       Impact factor: 2.754

6.  Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer.

Authors:  Toshiaki Saito; Tsutomu Tabata; Hitoshi Ikushima; Hiroyuki Yanai; Hironori Tashiro; Hitoshi Niikura; Takeo Minaguchi; Toshinari Muramatsu; Tsukasa Baba; Wataru Yamagami; Kazuya Ariyoshi; Kimio Ushijima; Mikio Mikami; Satoru Nagase; Masanori Kaneuchi; Nobuo Yaegashi; Yasuhiro Udagawa; Hidetaka Katabuchi
Journal:  Int J Clin Oncol       Date:  2017-11-20       Impact factor: 3.402

7.  Trends and Outcomes of Sentinel Lymph Node Biopsy in Early-stage Vulvar Squamous Cell Carcinoma: A Population-based Study.

Authors:  Juan Zhou; Wen-Wen Zhang; Xue-Ting Chen; San-Gang Wu; Jia-Yuan Sun; Qiong-Hua Chen; Zhen-Yu He
Journal:  J Cancer       Date:  2018-04-30       Impact factor: 4.207

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.